Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hakroush and TampePhilipp Gauckler, Andreas Kronbichler
6 January 2021
Correspondence on ‘Preliminary predictive criteria for COVID-19 cytokine storm’Desiree Tampe, Martin S Winkler, Peter Korsten, Samy Hakroush, Onnen Moerer, Björn Tampe
7 January 2021
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumoniaSamy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe
15 July 2020
Systemic lupus erythematosus and COVID-19: what we know so farGiuseppe A. Ramirez, Luca Moroni, Emanuel Della-Torre, Maria Gerosa, Lorenzo Beretta, Enrica P. Bozzolo, Lorenzo Dagna
28 August 2020
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’Enrique Calvo-Aranda, Irene Cañamares-Orbis, Marta Novella-Navarro, Alvaro Martinez-Alcala, Maria del Carmen Ortega de la O, Ismael Escobar-Rodriguez, Fernando Manuel Sanchez-Aranda
14 December 2020
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARDMaurizio Benucci, Arianna Damiani, Gianfranco Giannasi, Francesca Li Gobbi, Luca Quartuccio, Valentina Grossi, Maria Infantino, Mariangela Manfredi
6 July 2020
Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’Cloé Comarmond, Mathilde Leclercq, Gaëlle Leroux, Cindy Marques, Alexandre Le Joncour, Fanny Domont, Céline Hatte, Ségolène Toquet-Bouedec, Perrine Guillaume-Jugnot, Anne-Claire Desbois, Mathieu Vautier, Aude Rigolet, Yves Allenbach, Olivier Benveniste, David SaadounSee the full list of authors
12 November 2020
Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et alAdrian Ciurea, Axel Finckh
11 November 2020
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Calvo-Aranda et alSofia Ramiro, Rémy Mostard, Robert BM Landewé
14 December 2020
Correspondence on ‘prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’Jiyuan Shi, Ya Gao, Lili Zhang, Yang Zhao, Jianguo Xu, Jinhui Tian
10 November 2020
